Mara Tresansky, OD
Optometrist · Victor, NYNPI 1841963071
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,300 of the $16,656 with a category attached, or 91.9%. Astellas Pharma Global Development accounts for 91.9% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2024 at $15,465 and has fallen 96.4% since, to $551 in 2025. Among optometrist clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 35 payments — averaging $475.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma Global Development$15K
- Bausch & Lomb Americas Inc.$320
- Sight Sciences, Inc.$292
- Sun Pharmaceutical Industries Inc.$154
- Astellas Pharma US Inc$146
- Alcon$138
- plus $305 from 6 others
Across 5 payments — averaging $4740.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$24K
What the payments were for
- Consulting fees$15,30092%
- Food & beverage$1,3568%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma Global Development | 3 | $15,300 |
| Bausch & Lomb Americas Inc. | 7 | $320 |
| Sight Sciences, Inc. | 4 | $292 |
| Sun Pharmaceutical Industries Inc. | 3 | $154 |
| Astellas Pharma US Inc | 2 | $146 |
| Alcon | 7 | $138 |
| LKC Technologies, Inc. | 1 | $122 |
| Tarsus Pharmaceuticals, Inc. | 2 | $73 |
| Coopervision Inc. | 2 | $39 |
| Johnson & Johnson Vision Care, Inc. | 2 | $35 |
| Beaver-visitec International, Inc. | 1 | $19 |
| Aerie Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Izervay$15,300
- INFUSE$121
- OMNI(R) SURGICAL SYSTEM (US)$118
- TEARCARE SYSTEM$112
- CEQUA$100
How this compares
$16,656 in reported general payments places this provider in the 95th percentile of 2,743 optometrist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Latanoprost | 39 | $684 |
| Prednisolone Acetate | 13 | $425 |
| Timolol Maleate | 22 | $144 |
Paid to pharmacies, not to this prescriber.
Other optometrist in Victor
- Roy KlineLake Katrine$822K
- Susan ResnickNew York$463K
- Murray FingeretHewlett$374K
- Albert MorierSlingerlands$347K
- Denise WhittamNew York$343K
- Justin BazanBrooklyn$303K
- Jennifer TsaiNew York$275K
- Alexander KabiriQueens Village$268K
- Sophia VisanjiNew York$233K
- Jason ComptonNew York$181K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.